0001437749-25-020018.txt : 20250610 0001437749-25-020018.hdr.sgml : 20250610 20250610213025 ACCESSION NUMBER: 0001437749-25-020018 CONFORMED SUBMISSION TYPE: SCHEDULE 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250610 DATE AS OF CHANGE: 20250610 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Entero Therapeutics, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-89966 FILM NUMBER: 251038655 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: First Wave BioPharma, Inc. DATE OF NAME CHANGE: 20210921 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Ali Arif Nasir CENTRAL INDEX KEY: 0002072056 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SCHEDULE 13D/A MAIL ADDRESS: STREET 1: C/O NORTHWEST REGISTERED AGENT STREET 2: 8735 DUNWOODY PLACE STE N CITY: ATLANTA STATE: GA ZIP: 30350 SCHEDULE 13D/A 1 primary_doc.xml SCHEDULE 13D/A 0001437749-25-019912 0002072056 XXXXXXXX LIVE 1 Common stock, par value $0.0001 per share 06/06/2025 false 0001604191 33749P408 Entero Therapeutics, Inc.

777 YAMATO ROAD 777 YAMATO ROAD BOCA RATON FL 33431

Arif Nasir Ali 404 480 8000 1841 Chondra Dr Marietta GA 30062 Charlie Jarrett, Attorney 404 490 4060 2302 Parklake Drive NE Suite 420 Atlanta GA 30345 0002072056 N Ali Arif Nasir PF N X1 230900.00 0.00 230900.00 0.00 230900.00 N 4.9 IN Y Arif Ali IRA Roth PF N X1 0.00 0.00 0.00 0.00 147900.00 N 3.1 OO Y ANARP LLC WC N WY 0.00 0.00 0.00 0.00 62800.00 N 1.3 OO Y ANANRA LLC TRUST WC N GA 0.00 0.00 0.00 0.00 20200.00 N 0.4 OO Common stock, par value $0.0001 per share Entero Therapeutics, Inc. 777 YAMATO ROAD 777 YAMATO ROAD BOCA RATON FL 33431 This Amendment No. 1 amends the statement on Schedule 13D originally filed with the U.S. Securities and Exchange Commission on June 9, 2025 (together with all amendments through the date hereof, this "Schedule 13D"). This Schedule 13D relates to shares of common stock, $0.0001 par value per share (the "Common Stock"), of Entero Therapeutics, Inc., (the "Issuer"), whose principal executive offices are located at 777 Yamato Road, Suite 502, Boca Raton, Florida. As of June 6, 2025, the Reporting Persons beneficially owned in the aggregate 230,900 shares of Common Stock, constituting approximately 4.85% of the outstanding Common Stock. The following sets forth certain information with respect to shares of Common Stock directly beneficially owned by the Reporting Persons listed below: ANARP LLC beneficially owns 62800 shares of common stock representing 1.32% of the outstanding common stock. Arif Ali IRA Roth beneficially owns 147900 shares of common stock representing 3.10% of the outstanding common stock. ANANRA LLC TRUST beneficially owns 20200 shares of common stock representing 0.42% of the outstanding common stock. Arif Ali is the owner of Arif Ali IRA Roth, Manager of ANARP LLC and a Trustee of ANANRA LLC TRUST and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) of the Common Stock that Arif Ali IRA Roth, ANARP LLC and ANANRA LLC TRUST own. Mr. Ali has the sole power to vote or direct the vote or to dispose of 230,900 shares of Common Stock. None of Arif Ali IRA Roth, ANARP LLC or ANANRA LLC TRUST have power to vote or direct the vote or to dispose any shares of Common Stock. Beneficial ownership of the Common Stock shown on the cover pages of and set forth elsewhere in this statement for each of the Reporting Persons assumes that they have not formed a group for purposes of Section 13(d)(3) under the Exchange Act, and Rule 13d-5(b)(1) promulgated thereunder. If the several Reporting Persons were deemed to have formed a group for purposes of Section 13(d)(3) and Rule 13d-5(b)(1), the group would be deemed to own beneficially (and may be deemed to have shared voting and dispositive power over) in the aggregate 230,900 shares of Common Stock, constituting approximately 4.85% of the outstanding shares of Common Stock. The percentage of shares of Common Stock reported as being beneficially owned is based on 4,765,729 shares of Common Stock outstanding as reported in the 10Q report for quarter ending March 31, 2025 filed on May 15, 2025. The following sets forth certain information with respect to shares of Common Stock transacted by the Reporting Persons listed below since the most recent filing of Schedule 13D. Each of the below transactions was effected through the open market: ANARP LLC sold 20,000 shares of common stock on 6/6/2025 at $0.50 per share. Not applicable. The Reporting Persons ceased to be beneficial owners of 5% or more of shares of the Common Stock on June 6, 2025. Not applicable. Not applicable. Ali Arif Nasir Ali Arif Nasir 06/10/2025 Arif Ali IRA Roth Arif Ali IRA Roth 06/10/2025 ANARP LLC ANARP LLC 06/10/2025 ANANRA LLC TRUST ANANRA LLC TRUST 06/10/2025